Apr 19, 2023 / 12:00PM GMT
Gil Blum - Needham & Company - Analyst
Good morning, everyone, and welcome to the third day of the Needham & Company Healthcare Conference. My name is Gil Blum and I'm a senior biotech analyst here at Needham and Company, and I cover the gene therapy and immunology subsectors.
It is my pleasure to have with me this morning, Michael Parini, the CEO of Freeline Therapeutics. (Conference Instructions) And with that, Michael, you have the stage.
Michael Parini - Freeline Therapeutics Holdings plc - CEO & Director
Okay. Thanks, Gil. Really appreciate you inviting us to present this morning and thanks to Needham as well for including us. We're excited to share a bit about the Freeline story and talk about what we think will be a really exciting year ahead in 2023. Legal disclaimers.
At a high level, I wanted to talk a little bit about who Freeline is. Freeline is an AAV-directed gene therapy company really focused on treating chronic serious diseases. We were founded back in 2015 out of [UCL's lab] in England and really have invested
Freeline Therapeutics Holdings PLC at Needham Healthcare Conference (Virtual) Transcript
Apr 19, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers